Rick Bright

Rick Arthur Bright is an American immunologist, vaccine researcher, and public health official.

In 1984, he graduated from Hutchinson High School.

Following two years at the University of Kansas, he received a Bachelor of Science degree with a double major in biology (medical technology) and physical science (chemistry) from Auburn University-Montgomery.

From 1990 to 1992, Bright worked as a product manager in the Research & Development Department of Osborn Laboratories in Olathe, Kansas.

From 1994 to 1995, he was a research assistant in the Flow Cytometry Department of the Alabama Reference Lab in Montgomery, Alabama.

From 1997 to 2000, he worked at the Emory University Department of Microbiology and Immunology and in the Vaccine Research Center at the Yerkes National Primate Research Center in Atlanta, Georgia.

From 1998 to 2002, Bright worked at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, in the Influenza Branch, Immunology and Viral Pathogenesis Section, where he studied Influenza A virus subtype H5N1.

In 2002, he earned a Ph.D. in immunology and molecular pathogenesis (virology) from the Division of Biological and Biomedical Sciences at Emory University School of Medicine.

His dissertation was titled Studies on pathogenicity and control of H5N1 influenza A viruses in mice.

His doctoral advisor was Jacqueline Katz.

From 2002 to 2003, he shifted to working at the pharmaceutical company, Altea Therapeutics (a subsidiary of Nitto Denko) in Atlanta, Georgia, where he was a senior research scientist in their Vaccine and Immunology Programs.

In 2003, he rejoined the CDC as an immunologist/virologist in their Disease Control and Prevention, Influenza Division,

Strain Surveillance Branch in Atlanta, working on their influenza antiviral drug program and focusing on avian influenza.

He held that position until 2006.

From 2006 to 2008, Bright returned to working in the private sector of the biotechnology industry at Novavax in Maryland, where he was vice president of their global influenza programs as well as of their vaccine research and development.

For his work there, he was an adviser to the WHO and the U.S. Department of Defense (DOD) and became the recipient of the prestigious Charles C. Shepard Science Award for Scientific Excellence, jointly awarded by the CDC and the World Health Organization (WHO).

During that time, he also participated in WHO committees on vaccine development and pandemic preparedness.

In February 2008, Bright worked at the non-profit PATH on a Bill & Melinda Gates Foundation grant funded project as the director in vaccine manufacturing capacity building in Viet Nam.

In 2010, he completed the Advanced Course in Vaccinology (ADVAC) from the Fondation Mérieux and University of Geneva in Annecy, France.

He was also the scientific director of the influenza vaccine project as well as the global vaccine development program, a position he held until October 2010.

In 2010, Bright joined the U.S. Department of Health and Human Services (HHS) governmental agency Biomedical Advanced Research and Development Authority (BARDA).

He was the program lead of BARDA International Programs, then in June 2011 became acting chief of the influenza antiviral drug advanced development program, a position he held until December 2011.

From June 2011 to December 2015, he was both deputy director and acting director of BARDA's Influenza and Emerging Diseases Division, eventually serving as director of the division from December 2014 to November 2016.

He was the director of the Biomedical Advanced Research and Development Authority (BARDA) from 2016 to 2020.

From February 2016 to November 2016, he was an incident commander in the ASPR/BARDA Zika Response.

On November 15, 2016, after a competitive selection process, Office of the Assistant Secretary for Preparedness and Response (ASPR) director Nicki Lurie appointed Bright to the position of director of BARDA.

He succeeded founding director Robin Robinson.

In addition to his role as director of BARDA, he was also deputy assistant secretary for Preparedness and Response in the ASPR.

On October 29, 2019, two months prior to the COVID-19 pandemic, Bright participated in a meeting titled "Universal Flu Vaccine" at the Milken Institute School of Public Health with other government officials, including Anthony Fauci.

The meeting discussed a perceived need to "blow up the system" in-order to bypass regulatory control on mRNA vaccines.

Participants also discussed the need to create an "aura of excitement" and "make influenza sexy" in order to revive government funding and drive production of mRNA vaccines, which Bright and others considered superior to "traditional egg-based vaccines".

In May 2020, he filed a whistleblower complaint, alleging that the Trump administration ignored his early warnings about the COVID-19 pandemic and illegally retaliated against him by ousting him from his role and demoting him to a position at the National Institutes of Health.

On October 6, 2020, Bright resigned from the government.

On November 9 he was named a member of President-elect Joe Biden's coronavirus advisory board.

Bright was born and raised in Hutchinson, Kansas.

On April 20, 2020, in the midst of the COVID-19 pandemic in the United States, Bright was reassigned to the National Institutes of Health.

An HHS spokesperson said Bright's new role would be to help "accelerate the development and deployment of novel point-of-care testing platforms".

Bright challenged his transfer, stating that it was retaliation his insistence that the government address the pandemic by investing the billions of dollars allocated by Congress for that purpose in supplies and "safe and scientifically vetted solutions, and not in drugs, vaccines and other technologies that lack scientific merit."

He said such unproven drugs were being promoted by individuals with political connections and that he resisted these endeavors, which he called "cronyism."

Among these complaints, Bright objected to providing additional federal funding to Ridgeback Biotherapeutics to further develop molnupiravir into a treatment for COVID-19.